Symphony Health Review 2026

B2B Contact & Company Data

Last updated: 2026-06-03

Visit Symphony Health → See All B2B Data Tools

The Bottom Line

Symphony Health is for pharma commercial and analytics teams that need prescribing volume, market-share, and patient-journey data to drive strategy. The Integrated Dataverse gives you the scale to size markets, plan territories around real prescribing behavior, and diagnose where brands gain and lose patients across the prescription lifecycle. For organizations with the analysts to work the data, it's a credible source and a useful counterweight to IQVIA in the prescribing-data market.

The honest trade-off is that this is enterprise analytics, not a sales tool, and the corporate confusion is a real hazard. You won't pull contacts out of it, the pricing is steep enough to be hard for smaller pharma to justify, and buyers routinely mistake it for an IQVIA product when it actually sits under ICON plc following the PRA acquisition. Going in clear-eyed about both the scope and the lineage is essential.

Buy Symphony Health if you have a commercial-analytics function, need prescribing and patient-journey data for planning, and want a viable alternative to IQVIA in sourcing. Choose IQVIA if you need the broadest global coverage and the largest product portfolio. If your actual need is provider contacts to prospect rather than analytics, skip both and go to Definitive Healthcare or Provyx for data you can act on. And whatever you do, verify exactly which vendor and contract you're signing before you commit.

What is Symphony Health?

Symphony Health is a b2b contact & company data tool. Pharma prescribing analytics platform, now part of ICON plc (via PRA Health Sciences). Strong on prescription volume data and patient journey analytics. Less useful for direct sales prospecting, but valuable for territory planning and market sizing.

Best for: Pharma commercial teams that need prescribing volume data for territory planning

Best For

Pharma commercial teams that need prescribing volume data for territory planning

Symphony Health Overview

Symphony Health is a prescribing-analytics and pharmaceutical-data platform built around its Integrated Dataverse (IDV), a large pool of claims and prescriber information covering hundreds of millions of patients and roughly 1.8 million prescribers in the US. Pharma commercial teams use it for prescription volume, market share, and patient-journey analytics, the kind of intelligence that drives territory planning, brand strategy, and market sizing rather than day-to-day prospecting.

It's worth clearing up the corporate lineage, because it causes real confusion. Symphony Health was acquired by PRA Health Sciences in 2017, and PRA later merged into ICON plc in 2021. It is not an IQVIA product, even though it's frequently lumped in with IQVIA because both sell prescribing and claims data and both trace back to the IMS Health era data wars. If a vendor or listing tells you Symphony is part of IQVIA, that's inaccurate, and it matters when you're deciding which contract you're actually signing.

What Symphony does well is longitudinal prescription and claims analytics. It tracks how patients move through the prescription lifecycle, where switches and drop-offs happen, and how a brand's share evolves against competitors. For a commercial team trying to size a market, plan field deployment around real prescribing volume, or understand the patient journey for a launch, that depth is the product's reason to exist.

What it doesn't do is hand you contacts. You won't pull a list of prescribers with verified emails and direct dials out of Symphony, and it's not built for outbound sales workflows. It's an analytics and market-research platform for pharma strategy and planning. Smaller pharma teams also find it expensive, and the persistent confusion with IQVIA's products means buyers should be very clear about exactly which dataset and contract they're evaluating.

Pros & Cons

Deep prescribing volume and market-share dataSymphony's Integrated Dataverse pulls together claims and prescriber data across hundreds of millions of patients and around 1.8 million US prescribers. That scale supports detailed market-share tracking, brand performance analysis, and competitive benchmarking at the prescriber and geography level. For commercial teams that live and die by share trends, this depth is the core of the value.
Patient-journey analytics across the prescription lifecycleSymphony tracks how patients move through diagnosis, prescription, switches, and drop-off, which reveals where brands gain and lose patients. That longitudinal view is far more useful for strategy than a static snapshot of prescriptions written. Launch and brand teams use it to find the pressure points in the patient journey where a marketing or access intervention actually changes outcomes.
Strong fit for territory planning and market sizingBecause the data ties prescribing volume to geography and prescriber, it's well suited to deploying a field force where the treatable patients and high-volume prescribers actually are. Teams redraw territories around real prescription flow instead of population proxies. For a launch with a limited field force, that targeting can meaningfully improve coverage of the prescribers who matter most.
An established alternative in the prescribing-data marketSymphony has long been one of the few credible alternatives to the IMS Health and IQVIA lineage of prescribing data, and it competed hard enough to spark public disputes over data access and pricing. For buyers who want a counterweight to IQVIA in a sole-source negotiation, having a viable second source of prescribing data has real value beyond the dataset itself.

Not a prospecting toolSymphony is analytics, not a contact database. You won't export prescriber lists with verified emails and phone numbers for outbound sales. If your team needs contacts to sequence and call, you'll have to source them elsewhere and use Symphony only for the strategy and targeting layer. Buyers who expect a list-building tool will be disappointed.
Expensive, especially for smaller pharmaPrescribing and claims data at this scale carries enterprise pricing, and it's quoted custom with no public rates. For a small or emerging pharma team, the cost can be hard to justify against the breadth of analytics they'll actually use. The platform is built for commercial organizations with real analytics budgets, not lean launch teams watching every dollar.
Persistent confusion with IQVIA productsSymphony is constantly conflated with IQVIA, partly because both sell prescribing data and share roots in the IMS Health era. In reality Symphony sits under ICON plc via the PRA acquisition, not IQVIA. That confusion leads buyers to think they're evaluating one vendor when the contract, data, and roadmap belong to another. Confirm exactly whose product and contract you're signing.
Steeper learning curve than a contact toolGetting value out of claims and prescribing analytics requires analysts who know how to interpret longitudinal patient data, market-share methodology, and the quirks of claims coverage. It's not a tool a rep opens and immediately uses. Organizations without a commercial-analytics function to drive it will struggle to turn the data into decisions, leaving the spend underused.

Use Cases

Pharma Launch Team Sizing a New Market

A pharma company preparing to launch a treatment needs to know how large the addressable prescriber and patient population really is. Using Symphony's Integrated Dataverse, the commercial-analytics team quantifies how many patients are being diagnosed and treated for the target condition, which prescribers are writing for competing therapies, and where those prescribers cluster geographically. They build a market-sizing model grounded in real claims and prescribing volume rather than epidemiology estimates. The resulting forecast and field-deployment plan are defensible to leadership because they rest on observed prescribing behavior, and the launch field force is sized to actual opportunity rather than a guess.

Brand Team Diagnosing Patient Drop-Off

An established brand is losing share and the team can't tell whether the problem is new-patient acquisition or existing-patient retention. Symphony's patient-journey analytics let them follow patients through the prescription lifecycle and pinpoint where drop-off happens, for example patients abandoning therapy at the first refill. With that diagnosis, the brand team designs an adherence and access program targeted at the exact failure point rather than spending broadly. They measure improvement in persistence among the targeted cohort over the following quarters, recovering share they would have lost to undiagnosed churn.

Commercial Ops Realigning Sales Territories

A pharma commercial-operations team suspects its field territories are misaligned, with reps covering geographies that don't match where prescribing actually happens. Using Symphony's prescriber-level volume data, they map real prescription flow across the country and find that several territories are over- or under-resourced relative to opportunity. They redraw the territory map around observed prescribing volume and high-value prescribers. After realignment, the field force covers a higher share of the prescribers driving the brand's volume with the same headcount, improving call efficiency and reducing wasted coverage.

Key Features

Prescribing analytics
Market share data
Patient journey tracking
Territory planning
Claims analysis
Therapeutic area insights

Pricing

Plan	Price
Standard	Custom
Enterprise	Custom

Pricing as of 2026. Check Symphony Health's website for current pricing.

Pricing Analysis

Symphony Health uses custom, enterprise pricing with no public rates. Cost depends on which datasets you license (claims, prescriber, patient-journey), the therapeutic areas and geographies in scope, the depth of history, and how you want the data delivered. Like the rest of the prescribing-data market, it's quoted per engagement, and you'll work with a sales team to scope it.

Expect prescribing and claims data at this scale to be a significant annual commitment, which is why smaller pharma teams often find it hard to justify against the slice of analytics they'll actually use. There's no self-serve or entry tier in the way a contact-data tool offers, because the product assumes a commercial organization with analysts who'll work the data.

When evaluating, two things matter most. First, confirm exactly whose product and contract you're signing, since Symphony is routinely confused with IQVIA but sits under ICON plc following the PRA acquisition, and the dataset, methodology, and roadmap differ. Second, scope tightly to the therapeutic areas and geographies you need rather than licensing the broadest possible dataset, so you're not paying for claims coverage you'll never analyze.

Frequently Asked Questions

Is Symphony Health part of IQVIA?

No, despite the frequent confusion. Symphony Health was acquired by PRA Health Sciences in 2017, and PRA merged into ICON plc in 2021, so Symphony sits under ICON, not IQVIA. The two get conflated because both sell prescribing and claims data and trace back to the IMS Health era. When evaluating, confirm precisely which vendor's product and contract you're signing.

Can I get prescriber contact lists from Symphony Health?

No. Symphony is a prescribing-analytics and market-research platform, not a contact-data provider. It gives you prescription volume, market share, and patient-journey analytics, not exportable lists of emails and phone numbers. If you need prescriber contacts to run outbound sales, you'll source those from a data provider like IQVIA OneKey, Definitive Healthcare, or Provyx and use Symphony for strategy.

What is the Integrated Dataverse?

The Integrated Dataverse (IDV) is Symphony's core data asset, a large pool of claims and prescriber data covering hundreds of millions of US patients and roughly 1.8 million prescribers. It powers the platform's market-share tracking, prescribing analytics, and patient-journey analysis. The IDV's scale is what lets commercial teams build defensible market-sizing and targeting models from observed behavior rather than estimates.

Who should use Symphony Health?

Pharma commercial, brand, and analytics teams that need prescribing volume and patient-journey data for market sizing, territory planning, and brand strategy. It's a fit for organizations with a commercial-analytics function that can interpret claims data. It's a poor fit for teams that mainly need contacts to prospect, or for very small pharma watching every dollar, since pricing is enterprise-grade.

How does Symphony Health compare to IQVIA?

Both sell prescribing and claims data with deep US coverage. IQVIA is larger, has broader international reach, and a more extensive product portfolio. Symphony is often positioned as the more flexible, customizable alternative and a credible second source for buyers who want negotiating leverage against IQVIA. The right choice depends on coverage needs, budget, and whether you want a counterweight to IQVIA in sourcing.

Similar Tools

By Rome Thorndike

Reviewed by Rome Thorndike. Last verified 2026-06-03.

Pricing, features, and ratings are based on vendor documentation, public filings, product demos, and feedback from sales teams using these tools in production. We update reviews when vendors ship major releases or change pricing.